Rami Manochakian’s key highlights from WCLC24

WCLC is a major international event focused on the latest advancements in lung cancer research, treatment, and patient care. Organized by the International Association for the Study of Lung Cancer (IASLC), this conference brings together researchers, clinicians, and healthcare professionals to share knowledge, discuss innovations, and collaborate on strategies to improve outcomes for lung cancer patients.

This year, WCLC24 is being held in San Diego, from September 7th to 10th. In connection to that, Rami Manochakian shared several posts on his X account:

Empowering the Next Generation of Thoracic Oncology Leaders.

”The future of thoracic oncology is in GREAT hands!

The final meeting of the 2024 IASLC Academy with this OUTSTANDING group of early career physicians and researchers at WCLC24.

Honored to serve as academy co-chair with my amazing friend Christian Rolfo and GREAT faculty.”

Breakthrough Findings from HARMONi2.

”Hot off the press.

Just presented at the presidential symposium at IASLC WCLC24.

Results of HARMONi2 trial of Ivonescimab VS Pembrolizumab in advanced non-small cell lung cancer with programmed death-ligand 1 (PD-L1) expression greater than 1%.  

Significant increase in median progression-free survival (mPFS): 11.14 vs. 5.82 months (hazard ratio [HR] 0.51).

Benefit observed in:

• Programmed death-ligand 1 (PD-L1) low (1-49%) and high (>50%).
• Squamous or non-squamous.”

MARIPOSA Study Update.

”Hot off the press.

Just presented at IASLC WCLC24.

Longer follow-up (median 31.1 months) of MARIPOSA Study of Lazertinib plus Amivantamab versus Osimertinib for 1st line treatment of advanced EGFR-positive non-small cell lung cancer (NSCLC). 

• 3-Year survival 61% vs 53%.
• 3-year intracranial progression-free survival (PFS): 38% vs 18%.”

Advancements in Oncology Event.

”The amazing experts Narjust Florez and Jarushka Naidoo discussing the latest data in management of stage IV NSCLC with the great Oncology Brothers at ‘Advancement in oncology’ event with Oncology News Central.”

Small Cell Lung Cancer Treatment with Estela Rodriguez, Eric K. Singhi, and the Oncology Brothers.

”Very insightful panel discussion with the wonderful experts, Estela Rodriguez and Eric K. Singhi and the great Oncology Brothers on the latest in treatment of small cell lung cancer at ‘Advancement in oncology’ event with Oncology News Central.”

TROPION-Lung01 Study Results.

”Hot off the press.

Just published in Journal of Clinical Oncology in conjunction with presentation of overall survival data at IASLC WCLC24.

Results of TROPION-Lung01 Study of Datopotamab Deruxtecan Vs Docetaxel for Previously Treated Advanced NSCLC.”

Rami Manochakian is a thoracic medical oncologist at Mayo Clinic, Florida. He specializes in thoracic malignancies, including lung cancer, mesothelioma, and thymic tumors, he has dedicated his career to advancing the field of oncology.  He is also recognized as a leader in medical education, serving in various educational  roles at Mayo Clinic and national and international medical societies, including ASCO, ALA, and IASLC.

Find other posts about WCLC24 on oncodaily.com